Results 51 to 60 of about 12,336,620 (246)

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source

The malignant transformation potential of the oncogene STYK1/NOK at early lymphocyte development in transgenic mice

Biochemistry and Biophysics Reports
B-cell Chronic Lymphocytic Leukemia (B-CLL) is a malignancy caused by the clonal expansion of mature B lymphocytes bearing a CD5+CD19+ (B1) phenotype. However, the origin of B-CLL remains controversial. We showed previously that STYK1/NOK transgenic mice
Yin Yang, Li Liu, Haley O. Tucker
doaj   +1 more source

Advocating the need of a systems biology approach for personalised prognosis and treatment of B-CLL patients [PDF]

BioDiscovery, 2012
The clinical course of B-CLL is heterogeneous. This heterogeneity leads to a clinical dilemma: can we identify those patients who will benefit from early treatment and predict the survival?
Hemanth Tummala, Alexey Goltsov, Hilal S Khalil, Anne Sproul, Fiona Scott, Vanio Mitev, Nikolai Zhelev   +6 more
doaj   +3 more sources

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Germinal center trajectories and transcriptional signatures define CLL subtypes and their pathway regulators.

PLoS ONE
Chronic lymphocytic leukemia (CLL) is divided into unmutated (UM-CLL) and mutated (M-CLL) subtypes depending on somatic hypermutation (SHM) frequency in their immunoglobulin heavy chain V (IGHV) region. We previously demonstrated that CD27bright memory B
Ahmed Mohamed, Luca Giudice, José Basílio, Sabina Barresi, Pradeep Kumar Kopparapu, Vanda Friman, Marco Tartaglia, Tarja Malm, Andreas Tilevik, Ola Grimsholm   +9 more
doaj   +1 more source

A Case of Chronic Lymphocytic Leukemia in Two Brothers

Bezmiâlem Science, 2017
Monoclonal B-cell lymphocytosis is accepted as an important risk factor for developing lymphocytosis familial chronic lymphocytic leukemia (CLL) but does not meet the criteria for B-cell lymphoproliferative disease, and patients with
İlhami GÜLTEPE, Tuba ÖZKAN, Güven ÇETİN   +2 more
doaj   +1 more source

Anti-Tumor Necrosis Factor-α Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia

Case Reports in Dermatology, 2011
Psoriasis is a chronic immunologically-based inflammatory skin disease. B-chronic lymphocytic leukemia (B-CLL) is a form of leukemia characterized by the slow and progressive accumulation of monoclonal CD5+ B lymphocytes in peripheral blood, bone marrow,
Anna Balato, Serena Lembo, Teresa Cirillo, Matteo Megna, Annunziata Raimondo, Luisa Di Costanzo   +5 more
doaj   +1 more source

Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL).

, 2003
One fifth of B-cell chronic lymphocytic leukaemia (B-CLL) patients exhibit loss of heterozygosity (LOH) at 10q23.3, the site of the tumour suppressor PTEN. Microsatellite markers mapped complete LOH to 10q23.3 in 2/41 B-CLL (5%) and allelic imbalances in
Tobler A, Cenni B, Fey MF, Leupin N, Hügli B, Novak U, Graber HU   +6 more
core   +1 more source

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen, Anne Kirstine Boas, Emilie Clausen, Nicoline Elers Koch, Anne Byriel Walls, Lotte Stig Nørgaard, Michael Asger Andersen, Anissa Aharaz, Rikke Lundsgaard Nielsen, Olivia Bornæs, Juliette Tavenier, Baker Nawfal Jawad, Helle Gybel Juul‐Larsen, Esben Iversen, Ove Andersen, Lona Louring Christrup, Kim Peder Dalhoff, Morten Baltzer Houlind   +17 more
wiley   +1 more source

CD14 as a potential prognostic factor and Bcl-2 as a therapeutic target in egyptian B-Cell chronic lymphocytic leukemia patients

Journal of Applied Hematology, 2019
INTRODUCTION: B-cell chronic lymphocytic leukemia (B-CLL) is a unique lymphoproliferative disorder that scarcely occurs under the age of 40. B-CLL represents a neoplastic disorder caused primarily by defective programmed cell death and accompanied by a ...
Mohamed Mahmoud El-Khawanky, Mohamed Hanfy Morsy, Amina Mohamed Elnaggar, Ola Ali Hussin, Mohga Mahmoud Zaewer, Naglaa Ali Khalifa   +5 more
doaj   +1 more source